First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 20.77 USD -2.53% Market Closed
Updated: Jun 8, 2024

Denali Therapeutics Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Denali Therapeutics Inc
Net Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Net Income
-$137.3m
CAGR 3-Years
N/A
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income
$6B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
-$959m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
$4B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Denali Therapeutics Inc's Net Income?
Net Income
-137.3m USD

Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Net Income amounts to -137.3m USD.

What is Denali Therapeutics Inc's Net Income growth rate?
Net Income CAGR 5Y
-22%

Over the last year, the Net Income growth was 63%.